Neuropathology and Pathogenesis of Encephalitis Following Amyloid-β Immunization in Alzheimer's Disease

Brain Pathology

Volumn 14, Issue 1, 2004, Pages 11-20

  Ferrer, Isidre ^a,b   Boada Rovira, Mercé ^c,d   Sánchez Guerra, María Luisa ^e   Rey, María Jesús ^b   Costa Jussá, Frederic ^f  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Section of Neuroradiology   (Spain)

^d Institut Catala de Neurociencies Aplicades   (Spain)

^e Inst Catala de Neurociencies Apl   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD57 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; GRANZYME A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE P38; PREDNISONE; QS 21; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; B LYMPHOCYTE; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; ENCEPHALITIS; GIANT CELL; HUMAN; IMMUNIZATION; INFLAMMATION; MALE; MENINGOENCEPHALITIS; MICROGLIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; VASCULAR AMYLOIDOSIS;

EID: 1042265187     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2004.tb00493.x     Document Type: Article

References (50)

1. Atzori C, Guetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A (2001) Activation of JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropothol Exp Neurol 60:1190-11197.
2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med 6:916-919.
3. Behl C (1999) AD and oxidative stress: implications for novel therapeutic approaches. Progr Neurobiol 57:301-323.
4. Bhat RV, Budd SL (2002) GSK-3beta signaling: casting a wide net in Alzheimer's disease. Neurosignals 11:251-261.
5. Birmingham K, Frantz S (2002) Setback to Alzheimer vaccine studies. Nat Med 8:199-200.
6. Botchler M, Ditzel L, Groll M, Hartmann C, Huber R (1999) The proteasome. Annu Rev Biophys Biomol Struct 28:295-317.
7. Braak H, Braak E (1999) Temporal sequence of Alzheimer's disease-related pathology. In: Cerebral Cortex, vol 74: Neurodegenerative and age-related changes in structure and function of cerebral cortex, Peters A, Morrison JH (eds.), Chapter 14, pp. 475-512, Kluver Academic/Plenum Publishers: New York, Boston, Dordrecht, London, Moscow.
8. Bugiani O, Giaccone G, Verga L, Pollo B, Ghetti B, Frangione B, Tagliavini F (1990) Alzheimer patients and Down patients: Abnormal presynaptic terminals are related to cerebral pre-amyloid deposits. Neurosci Lett 119:56-59.
9. Check E (2002) Nerve inflammation halts trial for Alzheimer's drug. Nature 415:462.
10. Ciechanover A (1998) The ubiquitin-proteasome pathways: on protein death and cell life. EMBO J 17:7151-7160.
11. Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev 2:769-776.
12. Duyckaerts C, Dickson DW (2003) Neuropathology of Alzheimer's disease. In: Neurodegeneration: The molecular pathology of dementia and movement disorders, Dickson D (edit.), Chapter 2, pp. 47-65, ISN Neuropath Press: Basel.
13. Ferrer I, Barrachina M, Puig B (2002) Glycogen synthase kinase-3 (GSK-3) is associated with neuronal and glial hyper-phosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 104:583-591.
14. Ferrer I, Blanco R, Carmona M, Puig B (2001) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/ JNK-P), and calcium/ calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108:1397-1415.
15. Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, Rey MJ, Ribalta T (2001) Prion protein expression in senile plaques in Alzheimer's disease. Acta Neuropathol 101:49-56.
16. Ferrer I, Martí E, Tortosa A, Blasi J (1998) Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol 57:218-225.
17. Furuta A, Price DL, Parp CA, Troncoso JC, Xu ZS, Tangiuchi N, Martin LJ (1995) Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 146:357-362.
18. Herschko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479.
19. Higgins LS, Holtzmann DM, Rabins J, Mobley WC, Cordell B (1994) Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann Neurol 35:598-607.
20. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Christi MA, Horne P, Heslin D, French J, Mount HT et al (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
21. Jellinger KA, Attems J (2003) Incidence of cerebrovascular lesions in Alzheimer's disease: a post-mortem study. Acta Neuropathol 105:14-17.
22. Keck S, Nitsch R, Grune T, Ulrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 85:15-22.
23. Lassmann H, Fisher P, Jellinger K (1993) Synaptic pathology of Alzheimer's disease. Ann NY Acad Sci 24:59-64.
24. Layfield R, Alban A, Mayer RJ, Lowe J (2001) The ubiquitin protein catabolic disorders. Neuropathol Appl Neurobiol 27:171-179.
25. Lewis J, Dickson DW, Lin WL, Chrisholm L, Corral A, Jones G, Yen SH, Sahara Y, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowen E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
26. Li J, Reichsteiner M (2001) Molecular dissection of the 11S REG (PA28) proteasome activators. Biochimie 83:373-383.
27. Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9:133-146.
28. Masliah E (1998) Mechanisms of synaptic pathology in Alzheimer's disease. J Neural Transm 53:147-158.
29. Masliah E, Sisk A, Mallory M, Games D (2001) Neurofibrillary pathology in transgenic mice overexpressing V717F β-amyloid precursor protein. J Neuropathol Exp Neurol 60:357-368.
30. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
31. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9:448-452.
32. Pappolla MA, Omar RA, Kim KS, Robakis NK (1992) Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am J Pathol 140:621-628.
33. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of glycogen synthase kinase 3 beta (GSK-3β) for Alzheimer disease neurofibrillary tangle. J Neuropathol Exp Neurol 58:1010-1119.
34. Perry G, Castellani RJ, Hirai K, Smith MA (1998) Reactive oxygen species mediate cellular damage in Alzheimer's disease. J Alzheimer Dis 1:45-55.
35. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral haemorrhage after passive anti-Aβ immunotherapy. Science 298:1379.
36. Plemper RK, Hammond AL (2002) Protein degradation in human disease. In: Progress in molecular and sub-cellular biology, vol 29, Reboud-Ravaux M (edit.), Chapter 5, pp. 61-84, Springer-Verlag: Berlin, Heidelberg.
37. Rock KL, Goldberg AL (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739-771.
38. Roher AE, Kokjohn TA (2002) Of mice and men: the relevance of transgenic mice Aβ immunizations to Alzheimer's disease. J Alzheimer Dis 4:431-434.
39. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer disease model is associated with amyloid deposition. J Neurosci 22:3376-3385.
40. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D et al (1999) Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
41. Schwartz K, Eggers M, Soza A, Koszinowski UH, Kloetzel PM, Groettrup M (2000) The proteasome regulator PA28α/β can enhance antigen presentation without affecting 20S proteasome subunit composition. Eur J Immunol 30:3672-3679.
42. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001) Immunization with a non-toxic/nonfibrillar amyloid- homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159:439-447.
43. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlack SL, Tabaton M, Perry G (1998) Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70:2212-2215.
44. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochem Biophys Acta 1502:139-144.
45. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94:13287-13292.
46. Tanaka K, Tanahashi N, Tsurumi C, Yokota KY, Shimbara N (1997) Proteasomes and antigen processing. Adv Immunol 64:1-38.
47. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000) Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48:567-579.
48. Zhu X, Lee HG, Raina AK, Perry G, Smith MA (2002) The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 1:270-281.
49. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA (2001) Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76:435-441.
50. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59:880-888.